We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.'s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance.
Protagonist Therapeutics (PTGX) presents a compelling investment case following strong clinical progress and underappreciated fundamentals. The company, with a market cap of $3.6 billion and $615 million in net cash as of June 2025,...
Create a free account, or log in to read the full article
No credit card required.
We may use your email to send marketing emails about our services. Click here to read our privacy policy.